CIK 0001398733
- Non-accelerated filer
- Smaller reporting company
Aquestive Therapeutics, Inc.
Sign in to watch- Ticker
- AQST
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 208623253
- Phone
- +1 908-941-1900
- Business address
- 184 LIBERTY CORNER ROAD, SUITE 305, WARREN, NJ
- Former names
- MonoSol Rx, Inc.
- Open-market buys, last 90 days
- $99,331
- in 1 filing
- Open-market sales, last 90 days
- $297,289
- in 4 filings, $297K under 10b5-1 plans
Net −$197,958. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-08-18 | Maxwell John T. SVP-Chief Financial Officer | Sale | −3,000 | $8.00 | $24K | 150,614 |
| 2020-03-16 | Maxwell John T. SVP-Chief Financial Officer | Grant or award · Non-Qualified Stock Option (right to buy) | +60,000 | 60,000 | ||
| 2019-02-28 | Maxwell John T. SVP-Chief Financial Officer | Grant or award · Non-Qualified Stock Option (right to buy) | +95,000 | 95,000 | ||
| 2018-12-06 | Maxwell John T. SVP-Chief Financial Officer | Purchase | +5,000 | $8.87 | $44K | 153,614 |
| 2018-11-21 | Maxwell John T. SVP-Chief Financial Officer | Purchase | +10,000 | $9.80 | $98K | 148,614 |
| 2018-07-24 | Maxwell John T. SVP-Chief Financial Officer | Grant or award · Stock Option (Right to Purchase) | +36,120 | 36,120 |
Page 1 of 1 · 6 trades